HTT RNAi Conjugates for Blood-Brain Barrier CNS Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Huntington's disease do not alter the course of the disease, and there is a need for RNA interference agents that can selectively and efficiently inhibit the expression of the mutant HTT gene to provide long-term management.
Innovation Solution
Development of chemically modified small interfering RNAs (siRNAs) that target the HTT gene, combined with antigen binding proteins for selective delivery to CNS cells, to inhibit HTT gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for Huntington's disease, then current symptom management is achieved, but the disease course cannot be altered and long-term management is not provided
Solution Approach 1:
The patent employs continuous administration of RNAi agents to maintain sustained inhibition of HTT protein expression. The composition enables prolonged therapeutic effect through repeated dosing, ensuring continuous suppression of mutant protein production throughout the disease course, thereby transforming intermittent symptom management into continuous disease-modifying therapy.
Solution Approach 2:
The patent utilizes chemically modified siRNAs with specific nucleotide sequences and chemical modifications to optimize RNAi activity. By adjusting parameters such as nucleotide composition, modification patterns, and dosage regimens, the therapy achieves potent and durable inhibition of HTT expression, altering the natural progression of the disease.
2Measurement precision
If RNAi agents are designed to target HTT gene, then selective inhibition of mutant HTT expression is achieved, but delivery to CNS cells remains challenging
Solution Approach 1:
The patent employs antigen binding proteins as intermediary carriers that facilitate delivery of RNAi agents to CNS cells. These proteins bind to specific antigens on the surface of target cells, mediating the transport of therapeutic siRNAs across the blood-brain barrier and into the neuronal cytoplasm, thereby solving the delivery challenge while maintaining sequence-specific HTT inhibition.
Solution Approach 2:
The patent designs RNAi agents with specific nucleotide sequences and chemical modifications tailored to target HTT expression in particular CNS cell types. The composition exhibits localized activity in the brain, achieving selective inhibition in neurons and glial cells while minimizing off-target effects, thereby combining high selectivity with effective tissue-specific delivery.
3Productivity
If chemically modified siRNAs are used, then efficient HTT gene expression inhibition is achieved, but complexity of the therapeutic composition increases
Solution Approach 1:
The patent creates a composite therapeutic composition combining chemically modified siRNAs with antigen binding proteins and appropriate excipients. This composite formulation integrates multiple functional elements - the RNAi agents provide gene silencing activity while the protein carriers enable targeted delivery, and the combined system achieves efficient HTT inhibition through synergistic interaction of its components.
Solution Approach 2:
The patent optimizes multiple parameters of the siRNA composition including nucleotide sequence, chemical modifications, concentration, and formulation conditions to maximize HTT inhibition efficiency. By carefully controlling these parameters, the patent achieves potent gene silencing while managing the complexity of the chemical composition through standardized synthesis protocols and quality control measures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The HTT RNAi agents effectively reduce HTT protein expression, providing therapeutic benefits for neurodegenerative diseases such as Huntington's Disease.
Implementation Method 1
RNA interference (RNAi) agents, e.g., double stranded RNAi agents such as chemically modified small interfering RNAs (siRNAs), for inhibition of huntingtin ('HTT') gene expression
Data Source
AI summary
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a huntingtin (HTT) gene. The HTT RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an HTT gene. The HTT RNAi agents are conjugated to an antigen binding protein that may enable subcutaneous delivery of the RNAi agents by facilitating crossing of the blood brain barrier (BBB). Pharmaceutical compositions that include one or more HTT RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described HTT RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of HTT gene expression and a reduction in HTT activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including Huntington's Disease.